B+
Bull case
30%
Probability
Target price
$52.00
+21.0% vs current
TVTX
Travere TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+1Most likely
B
Base case
45%
Probability
Target price
$43.00
+0.1% vs current
B-
Bear case
25%
Probability
Target price
$34.00
-20.9% vs current
AI sentiment snapshot
Latest data as of 2026-05-04
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+50.0
Score
AI commentary
Headline tone is positive because recent coverage centered on FILSPARI's April 13, 2026 FDA approval in FSGS and the stock's sharp post-approval move. But this is still a monitoring-style T+1 earnings memo: as of May 4, 2026, the checked primary sources confirmed only the scheduled timing of the Q1 release, not the actual earnings results, guidance, analyst revisions, or a verified post-print market reaction. That missing earnings confirmation keeps conviction below what the strong pre-existing approval narrative alone would imply.
RankAlpha Sentiment Codex - 2026-05-04
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-04eventQ1 2026 earnings release timing is confirmed, but results were not yet verified in checked primary sourcesHigh impact
Travere said on April 27, 2026 that it plans to report first-quarter 2026 financial results on May 4, 2026 after the U.S. market close and host a 4:30 p.m. ET call; as of May 4, 2026, no Q1 earnings release or 8-K was verified in the primary sources checked, so earnings surprise, guidance changes, and analyst revisions remain unconfirmed [#IR-2026-04-27].
2026-06-30eventExpected first-half 2026 milestone payment can modestly support liquidityMedium impact
Travere's February 19, 2026 investor-relations earnings release said year-end cash, cash equivalents, and marketable securities were $322.8 million and that the company expects a $25 million sales-based milestone payment from Mirum Pharmaceuticals in the first half of 2026, which could modestly reinforce balance-sheet flexibility while the company funds launch and pipeline work [#IR-2026-02-19].
2026-06-30catalystFILSPARI FSGS launch conversion after April approvalHigh impact
Travere's April 13, 2026 8-K says FDA approved FILSPARI to reduce proteinuria in adult and pediatric FSGS patients without nephrotic syndrome, making it the first approved medicine for FSGS; the filing also says Travere estimates a U.S. addressable population of more than 30,000 and highlighted favorable DUPLEX subgroup data, so the next debate is how much of that approval converts into durable launch demand [#8-K-2026-04-14].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-04 • Updated nightlySource: Internal modelMethodology